Associated Genetic Biomarkers
NCI Definition: A malignant tumor arising from the endothelial cells of the blood vessels. Microscopically, it is characterized by frequently open vascular anastomosing and branching channels. The malignant cells that line the vascular channels are spindle or epithelioid and often display hyperchromatic nuclei. Angiosarcomas most frequently occur in the skin and breast. Patients with long-standing lymphedema are at increased risk of developing angiosarcoma. 
Angiosarcomas most frequently harbor alterations in TP53, MYC, KDR, PIK3CA, and FLT4 .
TP53 Mutation, MYC Amplification, TP53 c.217-c.1178 Missense, TP53 Missense, and KDR Mutation are the most common alterations in angiosarcoma .
There are 10 clinical trials for angiosarcoma, of which 9 are open and 1 is completed or closed. Of the trials that contain angiosarcoma as an inclusion criterion, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (6 open), and 1 is phase 3 (0 open).
PIK3CA and PTEN are the most frequent gene inclusion criteria for angiosarcoma clinical trials .
Nivolumab, pazopanib, and anti-endoglin chimeric monoclonal antibody trc105 are the most common interventions in angiosarcoma clinical trials.
Significant Genes in Angiosarcoma
PTEN is an inclusion eligibility criterion in 1 clinical trial for angiosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and angiosarcoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.